
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna is a clinical-stage biotechnology company with a promising pipeline of product candidates focused on three therapeutic areas. The company's proprietary Native Complex Platform is expected to unlock the full potential of GPCR therapies, giving it a strong competitive advantage. Based on positive Phase 1 trial results for SEP-479, a once-daily oral PTH1R agonist, and promising preclinical data for SEP-631, a MRGPRX2 receptor agonist, analysts are bullish on the company's potential success in the market. Septerna's strong financial position, with $516.5M in cash and marketable securities, and partnerships with companies like Novo Nordisk further support this positive outlook.
Bears say
Septerna is a clinical-stage biotechnology company with a narrow focus on GPCR oral small molecule drug discovery. Despite positive Phase 1 results for its lead candidate SEP-631, there is substantial risk for the company's planned Phase 2 studies given the disappointing data from Evommune's similar candidate. This risk, combined with the company's reliance on one single platform and narrow pipeline, leads to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares